Project A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF MPDL3280A (ANTI PD-L1…

Basic data

Title:
A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF MPDL3280A (ANTI PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN NAB-PACLITAXEL FOR CHEMOTHERAPY NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON SMALL CELL LUNG CANCER
Duration:
11/01/2016 to 10/01/2019
Abstract / short description:
A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF MPDL3280A (ANTI PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN NAB-PACLITAXEL FOR CHEMOTHERAPY NAÏVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON SMALL CELL LUNG CANCER
Keywords:
clinical trial
klinische Studie

Staff

Managers

Faculty of Medicine
University of Tübingen

Contact persons

Faculty of Medicine
University of Tübingen

Local organizational units

Department of Diagnostic and Interventional Radiology
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine

Funders

Nürnberg, Bayern, Germany
Help

will be deleted permanently. This cannot be undone.